InvestorsHub Logo
Followers 279
Posts 33513
Boards Moderated 1
Alias Born 11/14/2013

Re: None

Sunday, 02/18/2024 12:24:04 PM

Sunday, February 18, 2024 12:24:04 PM

Post# of 724222
Lifileucel, ONC Live screwed up four year survival.

Four year estimated survival for lifileucel treated melanoma (heavily pretreated unresectable and/or metastatic) was 21.9%. NCT02360579. https://oncologypro.esmo.org/meeting-resources/esmo-immuno-oncology-congress/long-term-efficacy-and-patterns-of-response-of-lifileucel-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-melanoma-a-4

ONC live incorrectly reported it as 47.3%
https://www.onclive.com/view/lifileucel-demonstrates-long-term-efficacy-and-survival-benefit-in-advanced-pretreated-melanoma
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News